All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

TRT and high hematocrit: is thick blood actually dangerous?

Alpha Club Supplements UK

TikTok creator

10.5K viewsWatch on TikTok→

Quick answer

Testosterone therapy reliably stimulates erythropoiesis, raising hematocrit in a significant proportion of users, with rates of erythrocytosis above 54% reported in roughly 3-18% of TRT patients depending on formulation and dose (Bhasin et al., 2018, JCEM). Current Endocrine Society guidelines recommend withholding TRT when hematocrit exceeds 54% until levels normalize, and therapeutic phlebotomy is a guideline-supported intervention, not an overcautious one. The risk profile does vary with individual cardiovascular and clotting history, but blanket reassurance without clinical context is not consistent with standard monitoring practice.

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.

What did @alphaclubsupps actually say?

The creator's core argument is that high hematocrit on TRT is overblown. He says guys "panic" when they see elevated numbers, but that for fit, active, well-hydrated men, running at 54-55% is "not so much to worry about." He also explicitly tells viewers not to rush to donate blood or reduce their dose.

To be fair, he does carve out exceptions: guys with high blood pressure, clotting disorders, or heavy smokers should "take it more into consideration." That's a real caveat. But the overall tone is dismissive, and that's where the problem starts. Telling a general audience not to panic and not to donate blood, without knowing their cardiovascular baseline, goes further than the evidence supports.

Does the science back this up?

Partially, but the reassuring framing is doing a lot of heavy lifting here. The risks of elevated hematocrit are real and dose-dependent, and they do not disappear just because someone is active and hydrated.

A 2018 meta-analysis by Corona et al. in Sexual Medicine Reviews found that testosterone therapy was associated with increased hematocrit, and that erythrocytosis (typically defined as hematocrit above 54%) was one of the most common adverse effects of TRT. More critically, a 2023 cardiovascular outcomes trial, the TRAVERSE study (Lincoff et al., New England Journal of Medicine), found that testosterone therapy did not significantly increase major adverse cardiovascular events overall, but the study population was monitored and managed. That is not the same as saying unmanaged erythrocytosis is safe.

The hematocrit-viscosity relationship is not linear. Blood viscosity rises sharply above 52-54%, increasing shear stress on vessel walls and raising thrombotic risk. Baskurt and Meiselman (2003, Seminars in Thrombosis and Hemostasis) documented this relationship clearly. Hydration helps, but it does not normalize viscosity at clinically elevated hematocrit levels. The "just stay hydrated" advice understates what is actually happening physiologically.

What did they get wrong (or right)?

He got the basic definition right. Hematocrit is the percentage of blood volume made up of red blood cells, and testosterone does reliably raise it. The normal reference range of 40-50% and the 52% flag threshold are accurate for most standard labs.

Where he goes wrong is the blanket reassurance. Telling viewers not to "run out and book a blood donation straight away" could actively delay a reasonable, clinician-recommended intervention. Therapeutic phlebotomy is a standard and well-supported management strategy for TRT-induced erythrocytosis, recommended in guidelines from the Endocrine Society (Bhasin et al., 2018, Journal of Clinical Endocrinology and Metabolism). It is not an overreaction.

He also implies that "guys on cycles" routinely running 54-55% sets some kind of precedent for safety. It does not. The fact that something is common among a population that often avoids medical supervision is not evidence that it is safe. That is a normalization argument, not a clinical one.

Credit where it is due: he correctly identifies that the risk picture changes with comorbidities. That nuance is accurate and worth saying.

What should you actually know?

Hematocrit above 52% on TRT should prompt a conversation with whoever is managing your care, not a solo decision about whether to panic or not. The Endocrine Society guidelines recommend against initiating or continuing TRT when hematocrit exceeds 54%, pending evaluation. That threshold exists for a reason.

Therapeutic phlebotomy, dose adjustment, or switching delivery method (injections tend to cause larger spikes than gels due to peak-and-trough pharmacokinetics) are all legitimate options that a clinician can help you weigh. Staying hydrated is sensible but it is supportive, not corrective.

If you are on a TRT protocol through a supervised platform, elevated hematocrit is exactly the kind of marker that should be reviewed before you decide it is nothing. The creator is right that not every elevated number is an emergency. He is wrong to suggest that doing research yourself and not donating blood is a reasonable substitute for medical guidance at those levels.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

TRT social video fact-checksMedical claim reviewProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Access rules depend on the compound and patient situation

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 5 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For TRT and high hematocrit: is thick blood actually dangerous?, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Provider decision path

Use local research to choose a safer review path

Direct answer

TRT and high hematocrit: is thick blood actually dangerous? is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.

Evidence check

Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.

Safety check

Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.

Next step

Compare providers, services and access requirements in the directory before contacting a suitable care team.

Claim path

Keep researching this testosterone and trt video claims cluster

Best for searchers turning TRT social claims into a safer lab-backed provider discussion.

Claim verdict

The useful answer behind this video

Claim being checked

Testosterone therapy reliably stimulates erythropoiesis, raising hematocrit in a significant proportion of users, with rates of erythrocytosis above 54% reported in roughly 3-18% of TRT patients depending on formulation and dose (Bhasin et al.

FormBlends verdict

Testosterone therapy reliably stimulates erythropoiesis, raising hematocrit in a significant proportion of users, with rates of erythrocytosis above 54% reported in roughly 3-18% of TRT patients depending on formulation and dose (Bhasin et al., 2018, JCEM). Current Endocrine Society guidelines recommend withholding TRT when hematocrit exceeds 54% until levels normalize, and therapeutic phlebotomy is a guideline-supported intervention, not an overcautious one. The risk profile does vary with individual cardiovascular and clotting history, but blanket reassurance without clinical context is not consistent with standard monitoring practice.

Patient-safe next step

Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • Testosterone therapy reliably stimulates erythropoiesis, raising hematocrit in a significant proportion of users, with rates of erythrocytosis above 54% reported in roughly 3-18% of TRT patients depending on formulation and dose (Bhasin et al., 2018, JCEM). Current Endocrine Society guidelines recommend withholding TRT when hematocrit exceeds 54% until levels normalize, and therapeutic phlebotomy is a guideline-supported intervention, not an overcautious one. The risk profile does vary with individual cardiovascular and clotting history, but blanket reassurance without clinical context is not consistent with standard monitoring practice.
  • Endocrine Society guidelines (Bhasin et al., 2018, JCEM) recommend withholding TRT when hematocrit exceeds 54%, pending clinical evaluation. That threshold is not arbitrary.
  • Therapeutic phlebotomy is a standard, guideline-supported intervention for TRT-induced erythrocytosis. Being told not to consider it is not neutral advice.

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compound access, legal status, and product quality still need a separate safety check.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.

Start provider review

What You'll Learn

  • Endocrine Society guidelines (Bhasin et al., 2018, JCEM) recommend withholding TRT when hematocrit exceeds 54%, pending clinical evaluation. That threshold is not arbitrary.
  • Therapeutic phlebotomy is a standard, guideline-supported intervention for TRT-induced erythrocytosis. Being told not to consider it is not neutral advice.
  • The TRAVERSE trial (Lincoff et al., 2023, NEJM) found no significant increase in major cardiovascular events with TRT, but participants were monitored. Unmanaged erythrocytosis was not part of that finding.
  • Blood viscosity increases sharply above 52-54% hematocrit, raising shear stress and thrombotic risk. Staying hydrated is supportive but does not correct the underlying erythrocytosis (Baskurt and Meiselman, 2003, Seminars in Thrombosis and Hemostasis).
  • Injection-based testosterone tends to produce larger hematocrit spikes than gels or patches due to peak-and-trough pharmacokinetics. Delivery method matters and is a clinical lever worth discussing with a provider.
  • The fact that elevated hematocrit is common among unsupervised users is not evidence that it is safe. Prevalence and safety are different things.
  • If your hematocrit is flagged on TRT labs, the right move is to discuss it with a clinician, not to self-assess your fitness level and move on.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

Alpha Club Supplements UK · TikTok creator

10.5K views on this video

High hematocrit freaks guys out on TRT… but should it? 🩸 It just means your blood is carrying more red cells. That’s why labs flag it when it creeps past 52%. Yes, thick blood can raise risk if you’ve got blood pressure issues, clotting problems, or you smoke. But for most guys on TRT, it’s not an instant crisis. The key is simple: monitor it, stay hydrated, and don’t overreact. Panic doesn’t fix numbers — smart management does. 💉

Sources & references

Citations extracted from our medical team's review. Click any citation to search PubMed.

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by Alpha Club Supplements UK, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.